Suppr超能文献

与常见辅助生殖技术(ART)治疗策略相关的人口趋势和活产率

Population trends and live birth rates associated with common ART treatment strategies.

作者信息

Chambers Georgina M, Wand Handan, Macaldowie Alan, Chapman Michael G, Farquhar Cynthia M, Bowman Mark, Molloy David, Ledger William

机构信息

National Perinatal Epidemiology and Statistics Unit, Centre for Big Data Research in Health and School of Women's and Children's Health, University of New South Wales, Level 1, AGSM Building, Sydney 2052, Australia

The Kirby Institute, University of New South Wales, Sydney 2052, Australia.

出版信息

Hum Reprod. 2016 Nov;31(11):2632-2641. doi: 10.1093/humrep/dew232. Epub 2016 Sep 22.

Abstract

STUDY QUESTION

Have ART live birth rates improved in Australia over the last 12 years?

SUMMARY ANSWER

There were striking improvements in per-cycle live birth rates observed for frozen/thaw embryo transfers, blastocyst transfer and single embryo transfer (SET), while live birth rates following ICSI were lower than IVF for non-male factor infertility in most years.

WHAT IS ALREADY KNOWN

ART and associated techniques have become the predominant treatment of infertility over the past 30 years in most developed countries. However, there are differences in ART laboratory and clinical practices, and success rates worldwide. Australia has one of the highest ART utilization rates and lowest multiple birth rates in the world, thus providing a unique setting to investigate the contribution of common ART strategies in an unrestricted population of patients to ART success rates.

STUDY DESIGN, SIZE, DURATION: A retrospective cohort study of 585 065 ART treatment cycles performed in Australia between 2002 and 2013 using the Australian and New Zealand Assisted Reproduction Database (ANZARD).

PARTICIPANTS MATERIALS, SETTING, METHOD: An unrestricted population of all women who underwent autologous ART treatment between 2002 and 2013. Visual descriptive analysis was used to assess the trends in ART procedures by the calendar years. Adjusted odds ratios (aORs) of a live birth for four common ART techniques were calculated after controlling for important confounders including female age, infertility diagnosis, stage of the embryo (blastocyst versus cleavage stage), type of embryo (fresh versus thawed), fertilization method (IVF versus ICSI) and number of embryos transferred (SET versus multiple embryos).

MAIN RESULTS AND THE ROLE OF CHANCE

The overall live birth rate per embryo transfer increased from 19.2% in 2002 to 23.3% in 2013 (21.9-24.3% for fresh embryo transfers and 14.6-23.3% for frozen/thaw embryo transfers). This occurred concurrently with an increase in SET from 29.7% to 78.9%, and an increase in the average age of women undergoing treatment from 35.0 to 35.9 years. Individuals who had a frozen/thaw embryo transfer cycle in 2002 had 43% (aOR: 0.57, 95% CI: 0.53-0.61) reduced odds of a live birth compared with a fresh embryo transfer cycle. This contrasted with 16% (aOR: 0.84, 95% CI: 0.80-0.98) reduced odds of a live birth from frozen/thaw embryo transfer cycles in 2013. In 2013, the odds of blastocyst transfer resulting in a live birth were more than twice as great as for cleavage stage transfer (aOR 2.01, 95% CI: 1.92-2.11). The adjusted odds of live birth per SET compared with multiple embryo transfer increased significantly over the last 12 years, from a 38% reduced odds of a live birth follow SET in 2002 (aOR: 062, 95% CI: 0.57-0.67) compared to an 8% reduced odds in 2013 (aOR: 0.92, 95% CI: 0.87-0.98). The aOR of a live birth using ICSI compared to IVF in non-male factor patients was lower in most years bringing into question its widespread use.

LIMITATION, REASONS FOR CAUTION: This is a retrospective cohort analysis and cannot confirm causality. High-level evidence on the effectiveness of particular ART techniques, particularly ICSI and blastocyst culture, requires prospective randomized controlled trials or detailed statistical analysis using large-scale data that counts for fertilization failure, embryo loss, prognostic factors and cycle characteristics.

WIDER IMPLICATION OF THE FINDINGS

The most striking improvements in ART success rates in Australia have been observed for frozen/thaw embryo transfers, blastocyst transfer and SET. Further studies of the role of ICSI in non-male factor infertility and blastocyst transfer success rates that take into account embryo loss are needed.

STUDY FUNDING/COMPETING INTERESTS: No funding was received to undertake this study. The authors declare that they do not have competing interests with this study.

TRIAL REGISTRATION NUMBER

NA.

摘要

研究问题

在过去12年中,澳大利亚的辅助生殖技术(ART)活产率是否有所提高?

总结答案

冷冻/解冻胚胎移植、囊胚移植和单胚胎移植(SET)的每个周期活产率有显著提高,而在大多数年份,对于非男性因素不孕,卵胞浆内单精子注射(ICSI)后的活产率低于体外受精(IVF)。

已知信息

在过去30年里,辅助生殖技术及相关技术在大多数发达国家已成为治疗不孕症的主要方法。然而,辅助生殖技术的实验室和临床实践以及全球成功率存在差异。澳大利亚是世界上辅助生殖技术利用率最高、多胎出生率最低的国家之一,因此提供了一个独特的环境来研究在不受限制的患者群体中常见辅助生殖技术策略对辅助生殖技术成功率的贡献。

研究设计、规模、持续时间:一项回顾性队列研究,使用澳大利亚和新西兰辅助生殖数据库(ANZARD),对2002年至2013年在澳大利亚进行的585065个辅助生殖治疗周期进行研究。

研究对象、材料、地点、方法:2002年至2013年期间接受自体辅助生殖治疗的所有女性组成的不受限制的群体。采用视觉描述性分析按历年评估辅助生殖技术程序的趋势。在控制了包括女性年龄、不孕诊断、胚胎阶段(囊胚与卵裂期)、胚胎类型(新鲜与解冻)、受精方法(IVF与ICSI)以及移植胚胎数量(SET与多个胚胎)等重要混杂因素后,计算四种常见辅助生殖技术活产的调整比值比(aORs)。

主要结果及机遇的作用

每次胚胎移植的总体活产率从2002年的19.2%提高到2013年的23.3%(新鲜胚胎移植为21.9 - 24.3%,冷冻/解冻胚胎移植为14.6 - 23.3%)。与此同时,SET从29.7%增加到78.9%,接受治疗的女性平均年龄从35.0岁增加到35.9岁。2002年进行冷冻/解冻胚胎移植周期的个体与新鲜胚胎移植周期相比,活产几率降低了43%(aOR:0.57,95%置信区间:0.53 - 0.61)。这与2013年冷冻/解冻胚胎移植周期活产几率降低16%(aOR:0.84,95%置信区间:0.80 - 0.98)形成对比。2013年,囊胚移植导致活产的几率是卵裂期移植的两倍多(aOR 2.01,95%置信区间:1.92 - 2.11)。与多胚胎移植相比,过去12年中SET的活产调整几率显著增加,2002年SET后活产几率降低38%(aOR:0.62,95%置信区间:0.57 - 0.67),而2013年降低8%(aOR:0.92,95%置信区间:0.87 - 0.98)。在大多数年份,非男性因素患者中使用ICSI与IVF相比的活产aOR较低,这使其广泛应用受到质疑。

局限性、谨慎原因:这是一项回顾性队列分析,无法确定因果关系。关于特定辅助生殖技术有效性的高级证据,特别是ICSI和囊胚培养,需要前瞻性随机对照试验或使用考虑受精失败、胚胎丢失、预后因素和周期特征的大规模数据进行详细统计分析。

研究结果的更广泛影响

在澳大利亚,冷冻/解冻胚胎移植、囊胚移植和SET的辅助生殖技术成功率有最显著的提高。需要进一步研究ICSI在非男性因素不孕中的作用以及考虑胚胎丢失情况下的囊胚移植成功率。

研究资金/利益冲突:未获得开展本研究的资金。作者声明他们与本研究不存在利益冲突。

试验注册号

无。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验